Want to see HK:1875 full AI Analyst Report?
Total Valuation
TOT BIOPHARM International Co. Ltd. has a market cap or net worth of HK$2.77B. The enterprise value is HK$2.11B.
Market CapHK$2.77B
Enterprise ValueHK$2.11B
Share Statistics
TOT BIOPHARM International Co. Ltd. has 772,787,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding772,787,900
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
TOT BIOPHARM International Co. Ltd.’s return on equity (ROE) is -0.16 and return on invested capital (ROIC) is -8.71%.
Return on Equity (ROE)-0.16
Return on Assets (ROA)-0.08
Return on Invested Capital (ROIC)-8.71%
Return on Capital Employed (ROCE)-0.09
Revenue Per Employee1.22M
Profits Per Employee-164.27K
Employee Count611
Asset Turnover0.59
Inventory Turnover3.39
Valuation Ratios
The current PE Ratio of TOT BIOPHARM International Co. Ltd. is ―. TOT BIOPHARM International Co. Ltd.’s PEG ratio is 0.04.
PE Ratio―
PS Ratio2.18
PB Ratio2.60
Price to Fair Value2.60
Price to FCF-60.47
Price to Operating Cash Flow131.29
PEG Ratio0.04
Income Statement
In the last 12 months, TOT BIOPHARM International Co. Ltd. had revenue of 747.64M and earned -100.37M in profits. Earnings per share was -0.14.
Revenue747.64M
Gross Profit388.98M
Operating Income-90.69M
Pretax Income-100.37M
Net Income-100.37M
EBITDA-6.44M
Earnings Per Share (EPS)-0.14
Cash Flow
In the last 12 months, operating cash flow was 16.14M and capital expenditures -43.07M, giving a free cash flow of -26.93M billion.
Operating Cash Flow16.14M
Free Cash Flow-26.93M
Free Cash Flow per Share-0.03
Dividends & Yields
TOT BIOPHARM International Co. Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.54
52-Week Price Change77.89%
50-Day Moving Average3.95
200-Day Moving Average3.37
Relative Strength Index (RSI)42.65
Average Volume (3m)240.51K
Important Dates
TOT BIOPHARM International Co. Ltd. upcoming earnings date is Aug 21, 2026, TBA (Not Confirmed).
Last Earnings DateMar 18, 2026
Next Earnings DateAug 21, 2026
Ex-Dividend Date―
Financial Position
TOT BIOPHARM International Co. Ltd. as a current ratio of 2.05, with Debt / Equity ratio of 61.29%
Current Ratio2.05
Quick Ratio1.66
Debt to Market Cap0.24
Net Debt to EBITDA-8.58
Interest Coverage Ratio-7.61
Taxes
In the past 12 months, TOT BIOPHARM International Co. Ltd. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
TOT BIOPHARM International Co. Ltd. EV to EBITDA ratio is -261.56, with an EV/FCF ratio of -62.52.
EV to Sales2.25
EV to EBITDA-261.56
EV to Free Cash Flow-62.52
EV to Operating Cash Flow104.30
Balance Sheet
TOT BIOPHARM International Co. Ltd. has HK$328.47M in cash and marketable securities with HK$383.72M in debt, giving a net cash position of -HK$55.25M billion.
Cash & Marketable SecuritiesHK$328.47M
Total DebtHK$383.72M
Net Cash-HK$55.25M
Net Cash Per Share-HK$0.07
Tangible Book Value Per ShareHK$0.83
Margins
Gross margin is 52.03%, with operating margin of -12.13%, and net profit margin of -13.42%.
Gross Margin52.03%
Operating Margin-12.13%
Pretax Margin-13.42%
Net Profit Margin-13.42%
EBITDA Margin-0.86%
EBIT Margin-10.77%
Analyst Forecast
The average price target for TOT BIOPHARM International Co. Ltd. is HK$4.40, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$4.40
Price Target Upside76.00% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-32.12%
EPS Growth Forecast-374.47%